Clinical meaning
At the molecular level, separation anxiety disorder involves dysregulation of the corticotropin-releasing factor (CRF) system, which serves as the primary mediator of the stress response. CRF neurons in the central nucleus of the amygdala (CeA) project to the paraventricular nucleus of the hypothalamus, activating the HPA axis and stimulating adrenocorticotropic hormone (ACTH) release from the anterior pituitary, which drives cortisol production from the adrenal cortex. In pathological anxiety, CRF receptor type 1 (CRF1) upregulation in the amygdala creates a feed-forward loop of heightened threat sensitivity. Glucocorticoid receptor (GR) polymorphisms, particularly the BclI and N363S variants, alter negative feedback sensitivity of the HPA axis, predisposing to chronic cortisol elevation and anxiety vulnerability. Epigenetic mechanisms play a critical role: early-life stress induces hypermethylation of the NR3C1 gene (encoding the glucocorticoid receptor) promoter region, reducing GR expression in the hippocampus and impairing cortisol negative feedback. This mirrors findings from rodent models where maternal separation alters DNA methylation patterns at stress-regulatory genes, producing lasting anxiety phenotypes. Neuroimaging studies using functional MRI reveal amygdala hyperreactivity to separation-related stimuli and reduced prefrontal cortical activation during emotion regulation tasks in children with SAD. Structural MRI shows increased amygdala volume and altered white matter tract integrity in the uncinate fasciculus (the primary connection between the prefrontal cortex and amygdala) in anxious youth. The serotonergic system is central to treatment: the 5-HTTLPR polymorphism (short allele) in the serotonin transporter gene (SLC6A4) is associated with increased amygdala reactivity and anxiety vulnerability, particularly in the context of environmental adversity (gene-environment interaction).